These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29241827)

  • 1. Prevalence and risk factors for kidney stones in fibrodysplasia ossificans progressiva.
    Gupta RR; Delai PLR; Glaser DL; Rocke DM; Al Mukaddam M; Pignolo RJ; Kaplan FS
    Bone; 2018 Apr; 109():120-123. PubMed ID: 29241827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization.
    Pignolo RJ; Hsiao EC; Baujat G; Lapidus D; Sherman A; Kaplan FS
    Orphanet J Rare Dis; 2021 Aug; 16(1):350. PubMed ID: 34353327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological symptoms in individuals with fibrodysplasia ossificans progressiva.
    Kitterman JA; Strober JB; Kan L; Rocke DM; Cali A; Peeper J; Snow J; Delai PL; Morhart R; Pignolo RJ; Shore EM; Kaplan FS
    J Neurol; 2012 Dec; 259(12):2636-43. PubMed ID: 22752062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of the noggin (NOG) and of the activin A type I receptor (ACVR1) genes in a series of twenty-seven French fibrodysplasia ossificans progressiva (FOP) patients.
    Lucotte G; Houzet A; Hubans C; Lagarde JP; Lenoir G
    Genet Couns; 2009; 20(1):53-62. PubMed ID: 19400542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
    Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients.
    Carvalho DR; Navarro MM; Martins BJ; Coelho KE; Mello WD; Takata RI; Speck-Martins CE
    Clin Genet; 2010 Feb; 77(2):171-6. PubMed ID: 19796185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
    Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
    Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases.
    Baujat G; Choquet R; Bouée S; Jeanbat V; Courouve L; Ruel A; Michot C; Le Quan Sang KH; Lapidus D; Messiaen C; Landais P; Cormier-Daire V
    Orphanet J Rare Dis; 2017 Jun; 12(1):123. PubMed ID: 28666455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.
    Pignolo RJ; Bedford-Gay C; Liljesthröm M; Durbin-Johnson BP; Shore EM; Rocke DM; Kaplan FS
    J Bone Miner Res; 2016 Mar; 31(3):650-6. PubMed ID: 27025942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
    Takahashi M; Katagiri T; Furuya H; Hohjoh H
    Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
    Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
    Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva.
    Mantick N; Bachman E; Baujat G; Brown M; Collins O; De Cunto C; Delai P; Eekhoff M; Zum Felde R; Grogan DR; Haga N; Hsiao E; Kantanie S; Kaplan F; Keen R; Milosevic J; Morhart R; Pignolo R; Qian X; di Rocco M; Scott C; Sherman A; Wallace M; Williams N; Zhang K; Bogard B
    Bone; 2018 Apr; 109():285-290. PubMed ID: 28866367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP).
    Pignolo RJ; Durbin-Johnson BP; Rocke DM; Kaplan FS
    Bone; 2018 Apr; 109():124-133. PubMed ID: 28627475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
    Sekimata K; Sato T; Sakai N
    Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).
    Kaplan FS; Al Mukaddam M; Pignolo RJ
    Bone; 2018 Apr; 109():158-161. PubMed ID: 28600150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
    Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
    Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP).
    Kaplan FS; Al Mukaddam M; Pignolo RJ
    Bone; 2017 Aug; 101():123-128. PubMed ID: 28465250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
    Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
    J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
    Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
    J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.